Researchers at Weill Cornell Medicine and the University of Adelaide have developed GoT-Multi, a tool that tracks multiple ...

Several pharmaceutical companies showcased data on their BTK inhibitors at the ASCO 2023 conference, including Ono ...

NRIX stock is rated Strong Buy as bexobrutideg advances in CLL trials. See here for NRIX stock's milestones, market potential ...

A new tool developed by Weill Cornell Medicine and the University of Adelaide investigators has enhanced the ability to track multiple gene mutations while simultaneously recording gene activity in ...

A new tool developed by Weill Cornell Medicine and the University of Adelaide investigators has enhanced the ability to track ...

A new tool developed by Weill Cornell Medicine and the University of Adelaide investigators has enhanced the ability to track ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today ...

NEW YORK – Kernal Biologics on Tuesday said the Advanced Research Projects Agency for Health (ARPA-H) awarded the company up to $48 million to support development of its in vivo mRNA-encoded CAR ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to UB-VV111 for the treatment of ...

Funds will advance in vivo CAR T-cell program and aims to improve cancer care by providing CAR T-cell therapies at a lower cost to patients ...

From bispecific engineering to clinically relevant data sourcing, evolving antibody technologies advance oncology therapeutics.

The go-ahead for Novartis’ oral treatment marks a new option for patients with spontaneous urticaria who remain symptomatic ...